Crossmark Global Holdings Inc. boosted its stake in Immunocore Holdings plc (NASDAQ:IMCR - Free Report) by 36.7% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 38,020 shares of the company's stock after acquiring an additional 10,217 shares during the quarter. Crossmark Global Holdings Inc. owned 0.08% of Immunocore worth $1,121,000 as of its most recent filing with the SEC.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Envestnet Asset Management Inc. boosted its stake in shares of Immunocore by 0.9% in the second quarter. Envestnet Asset Management Inc. now owns 70,571 shares of the company's stock worth $2,392,000 after acquiring an additional 606 shares during the last quarter. Pier Capital LLC lifted its holdings in Immunocore by 1.4% in the 3rd quarter. Pier Capital LLC now owns 82,480 shares of the company's stock valued at $2,568,000 after purchasing an additional 1,174 shares in the last quarter. Exchange Traded Concepts LLC boosted its stake in Immunocore by 40.4% during the 3rd quarter. Exchange Traded Concepts LLC now owns 5,075 shares of the company's stock worth $158,000 after purchasing an additional 1,461 shares during the last quarter. Assetmark Inc. grew its holdings in shares of Immunocore by 6.5% during the third quarter. Assetmark Inc. now owns 30,555 shares of the company's stock worth $951,000 after buying an additional 1,878 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its position in shares of Immunocore by 69.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 7,433 shares of the company's stock valued at $231,000 after buying an additional 3,053 shares during the last quarter. Hedge funds and other institutional investors own 84.50% of the company's stock.
Immunocore Trading Up 0.9 %
Shares of NASDAQ IMCR traded up $0.30 during mid-day trading on Friday, reaching $33.00. 180,947 shares of the company's stock were exchanged, compared to its average volume of 240,634. The firm has a market capitalization of $1.65 billion, a price-to-earnings ratio of -34.74 and a beta of 0.76. Immunocore Holdings plc has a 52-week low of $27.69 and a 52-week high of $76.98. The company's 50-day moving average is $30.53 and its 200-day moving average is $33.36. The company has a debt-to-equity ratio of 1.03, a quick ratio of 3.76 and a current ratio of 3.78.
Immunocore (NASDAQ:IMCR - Get Free Report) last announced its earnings results on Wednesday, November 6th. The company reported $0.17 earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.50. Immunocore had a negative net margin of 15.87% and a negative return on equity of 12.84%. The company had revenue of $80.25 million during the quarter, compared to analyst estimates of $78.94 million. During the same quarter last year, the firm posted ($0.59) earnings per share. Immunocore's revenue was up 23.7% compared to the same quarter last year. Analysts expect that Immunocore Holdings plc will post -0.94 EPS for the current fiscal year.
Analyst Ratings Changes
A number of equities analysts recently weighed in on the stock. UBS Group assumed coverage on shares of Immunocore in a research report on Thursday, October 24th. They set a "sell" rating and a $24.00 price target on the stock. Mizuho lowered Immunocore from an "outperform" rating to a "neutral" rating and dropped their price target for the company from $72.00 to $38.00 in a research report on Monday, November 11th. HC Wainwright reaffirmed a "buy" rating and issued a $100.00 price target on shares of Immunocore in a report on Thursday, October 24th. Morgan Stanley reissued an "equal weight" rating and set a $35.00 price objective (down previously from $74.00) on shares of Immunocore in a research note on Friday, December 13th. Finally, Guggenheim cut Immunocore from a "buy" rating to a "neutral" rating in a report on Monday, October 7th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and eight have given a buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $65.64.
Check Out Our Latest Stock Analysis on IMCR
Immunocore Profile
(
Free Report)
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.
Featured Articles
Before you consider Immunocore, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunocore wasn't on the list.
While Immunocore currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
